Loading clinical trials...
Loading clinical trials...
A Phase II Study of Dacomitinib in Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer (NSCLC) Patients Who Have Non-irradiated Brain Metastasis
Conditions
Interventions
Dacomitinib
Locations
1
South Korea
Jong-Mu Sun
Seoul, South Korea
Start Date
December 7, 2020
Primary Completion Date
September 1, 2022
Completion Date
March 1, 2023
Last Updated
January 5, 2021
NCT07485114
NCT06066138
NCT05692635
NCT05098132
NCT06284317
NCT06731413
Lead Sponsor
Samsung Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions